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Abstract: Background and objectives: Breast cancer is the most common cancer among women
worldwide. Early stage diagnosis is important for predicting increases in treatment success rates
and decreases in patient mortality. Recently, circulating biomarkers such as circulating tumor cells,
circulating tumor DNA, exosomes, and circulating microRNAs have been examined as blood-based
markers for the diagnosis of breast cancer. Although miR-202 has been studied for its function or
expression in breast cancer, its potential diagnostic value in a clinical setting remains elusive and
miR-202 has not been investigated in South Korea. In this study, we aimed to evaluate the diagnostic
utility of miR-202 in plasma samples of breast cancer patients in South Korea. Materials and Methods:
We investigated miR-202 expression in the plasma of 30 breast cancer patients during diagnosis along
with 30 healthy controls in South Korea by quantitative reverse transcription PCR. Results: The results
showed that circulating miR-202 levels were significantly elevated in the breast cancer patients
compared with those in healthy controls (p < 0.001). The sensitivity and specificity of circulating
miR-202 were 90.0% and 93.0%, respectively. Additionally, circulating miR-202 showed high positivity
at early stage. The positive rate of miR-202 was as follows: 100% (10/10) for stage I, 90% (9/10) for stage
II, and 80% (8/10) for stage III. miR-202 was also a predictor of a 9.6-fold high risk for breast cancer
(p < 0.001). Conclusions: Additional alternative molecular biomarkers for diagnosis and management
of pre-cancer patients are needed. Circulating miR-202 might be potential diagnostic tool for detecting
early stage breast cancer.
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1. Introduction
Breast cancer is one of the common causes of cancer-mediated deaths among women worldwide.
According to the World Health Organization (WHO), 1.5 million newly diagnosed cases and
570,000 deaths related to breast cancer were recorded in 2012. Breast cancer represents approximately
25% of total cancer cases and 15% of total deaths among women [1]. In the Republic of Korea, a total of
19,142 incidences of breast cancer with 2338 mortalities were reported in 2015 [2].
Despite continuous advancements in diagnosis methods, early diagnosis and improvement in
survival are still difficult. The early detection and application of improved treatment are extremely
important to improve the survival and quality of life for breast cancer patients. Along with simplicity,
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rapidness, and non-invasiveness, blood-based tumor markers are playing an increasingly important
role in the diagnosis and treatment of breast cancer.
MicroRNAs (also known as miRNA or miR) are non-cording RNAs (19–25 nucleotides long)
involved in the regulation of various cellular processes [3,4]. miRNAs bind to the 3′-untranslated
regions (UTRs) of the target mRNAs, thereby either inhibiting their translation or inducing
their sequence-specific degradation, leading to the silencing of respective gene expression.
miRNAs regulating the expression of target mRNAs that promote tumor growth, invasion, angiogenesis,
metastasis, and immune evasion have emerged as one of the major components in cancer biology [5–9].
miRNAs circulating in the blood have been identified, and their profiles reflect the variety of cancer
types, suggesting that their circulating population is partly derived from cancer [10,11].
Recent studies have demonstrated that miR-202 is associated with several types of cancers such as
ovarian cancer [12], lung cancer [13], and colorectal cancer [14]. miR-202 has been reported to have
either a tumor-suppressive or oncogenic function (Table 1) [15–28].
Table 1. Clinical characteristics of miR-202 in tissue and blood samples.
Cancer Type Sample Expression Level Functions Target Reference
Tissue samples
Chen et al. 2019 endometrial cancer tissue down cell migration, invasion FGF2 [15]
Wu et al. 2019 myocardial ischemia-reperfusioninjury mouse up cell apoptosis TRPM6 [16]
Han et al. 2019 cervical cancer tissue up cell migration, invasion, EMT MALAT1 [17]
Ke et al. 2018 colorectal cancer tissue down growth, metastasis SMARCC1 [18]
Yang et al. 2017 glioma tissue down growth, metastasis MTDH [19]
Jiang et al. 2016 lung cancer tissue down cell cycle arrest, apoptosis cyclin D1 [20]
Meng et al. 2016 esophageal squamous cell carcinoma tissue down cell proliferation, migration LAMA1 [21]
Wang et al. 2014 colorectal cancer tissue down cell migration, proliferation ARL5A [22]
Blood samples
Ma et al. 2016 esophageal squamous cell cancer blood down cell migration, invasion - [23]
Joosse et al. 2014 Breast cancer blood up metastasis, poor survival outcome - [24]
This discrepancy is presumed to be the result of differences in the sample processing methods,
type of samples, detection methods, and characteristics of the recruited study groups. Some studies
showed that miR-202 was significantly upregulated in breast cancer patients compared with that
in healthy controls [24]. Additionally, it was highly expressed in the drug-resistant breast cancer
tissues [25]. However, some studies reported that it was downregulated in breast cancer cells and
inhibited the tumorigenesis of breast cancer [27,28]. Although miR-202 has been studied for its function
or expression in breast cancer, little is known about its potential diagnostic value in a clinical setting.
miR-202 has not been investigated in South Korea. Here, we evaluated the diagnostic utility of miR-202
in plasma samples of breast cancer patients in South Korea. Furthermore, miR-202-based risk prediction
for diagnosing breast cancer was investigated.
2. Materials and Methods
2.1. Clinical Samples
Plasma samples of 30 breast cancer patients (stages I–III) from the Department of Surgery,
Yonsei Severance Hospital, Seoul, Republic of Korea, between 2011 to 2015 were used for miR-202
expression analysis (Table 2). Data such as the age and Tumor-Node-Metastasis (TNM) stage of total
30 breast cancer patients were obtained from patients’ electrical medical records. For healthy control,
plasma samples were obtained from 30 healthy donors. This study was approved by the institutional
ethics committee at Yonsei Severance Hospital (approval no.: 4-2011-0011, date: 7 March 2011).
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Table 2. Clinical characteristics of breast cancer patients.
Variable No. of Cases Percentage Mean Age (Range)
TNM stage
I 10 33.3 48.7 (34–60)
II 10 33.3 55.2 (31–76)
III 10 33.3 54.6 (38–73)
TNM, Tumor-Node-Metastasis.
2.2. miRNA Extraction
For the extraction of miRNAs from plasma, the NuceloSpin®miRNA Plasma kit (Macherely-Nagel,
Düren, Germany) was used according to the manufacturer’s instructions. All the preparation and
handling procedures were conducted under RNase-free conditions. Extracted miRNA was stored at
−80 ◦C until used.
2.3. miRNA Expression Analysis
Complementary DNA (cDNA) was synthesized using the TaqMan microRNA Reverse Transcriptase
kit (Applied Biosystems by Life Technologies, Foster City, CA, USA) according to the manufacturer’s
recommendations. Briefly, 5 µL of miRNA was used for cDNA synthesis. Reverse transcriptase (RT)
mixture contained 0.15 µL of 100 mM dNTP mix (100 mM of each dATP, dGTP, dCTP, and dTTP),
1 µL of 50 U/µL reverse transcriptase, 1.5 µL of 10× reverse transcriptase buffer, 0.19 µL of 20 U/µL
RNase inhibitor, and 3 µL of miRNA-specific primer. The volume of RT mixture was adjusted to 15 µL
with nuclease-free water. The following primers of TaqMan small RNA assays (Applied Biosystems by
Life Technologies) were used: hsa-miR-16 and hsa-miR-202. The temperature profile for cDNA synthesis
reaction was: 16 ◦C for 30 min, 42 ◦C for 30 min, and 85 ◦C for 5 min.
The miRNA expression was quantified by determining the cycle threshold (CT), which is
the number of PCR cycles required for the fluorescence to exceed a value significantly higher
than the background fluorescence, using the TaqMan small RNA assays (Applied Biosystems by
Life Technologies) with miRNA-specific primers according to the manufacturer’s instructions [29].
Briefly, 1.4 µL of cDNA was added to 10 µL of probe qPCR mix with 1 µL of miRNA-specific primer
and 7.6 µL of nuclease-free water in the final volume of 20 µL. RT-qPCR reactions were performed
on the CFX96 Real-Time PCR System Detector (Bio-Rad, Hercules, CA, USA). Samples were run in
duplicate for each experiment. Data were analyzed using the comparative ∆∆CT method (2−∆∆CT)
with miR-16 as an endogenous control for plasma [30–32]. To monitor contamination of the reagents, a
negative control was included for each primer pair. PCR cycling conditions were as follows: 95 ◦C for
10 min, 40 cycles of 95 ◦C for 15 s, and 60 ◦C for 60 s.
2.4. Statistical Analyses
All the statistical analyses were performed using GraphPad Prism version 6.0 (La Jolla, CA, USA)
and SPSS Statistics version 21.0 (IBM, Armonk, NY, USA). Student’s t-test was used for comparing
miR-202 expression between normal and cancer plasma samples, as well as to investigate miR-202
expression in the patients according to TNM stage. To assess the diagnostic utility of miR-202,
the receiver operating characteristic (ROC) curve analysis was performed and the area under the ROC
curve (AUC) was calculated. The risk of breast cancer for miR-202 was analyzed by the chi-square
test. Each stage of breast cancer was compared with healthy control. The effects were reported as
odds ratios (ORs) and 95% confidence intervals (CIs). In all the analyses, p < 0.05 was considered
statistically significant.
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3. Results
3.1. Patients’ Characteristics
Blood samples were collected from 30 breast cancer patients who did not receive any anti-tumor
treatment. The characteristics of the subjects involved in this study are shown in Table 2. The age of
these 30 patients ranged from 31 to 76 years. There were 10 patients with stage I (33.3%), 10 with stage
II (33.3%), and 10 with stage III (33.3%) breast cancer.
3.2. Diagnostic Value of Circulating miR-202
To investigate the diagnostic utility of miR-202 in plasma samples, its expression levels were
investigated by RT-qPCR, which were significantly higher in the breast cancer patients than in the healthy
controls (p < 0.001; Figure 1a). The diagnostic performance of miR-202 was determined by the analysis
of ROC curve. The area under the ROC curve (AUC) of miR-202 was 0.9500 (95% CI, 0.8842–1.016,
p < 0.0001; Figure 1b). At the cut-off value of 2.1, the sensitivity, specificity, positive predictive value,
and negative predictive value of miR-202 were 90.0% (95% CI, 73.5–97.9), 93.3% (95% CI, 77.9–99.2),
90.3% (95% CI, 76.1–96.5), and 93.1% (95% CI, 77.9–98.1), respectively (Figure 1c).
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3.3. Circulating miR-202 Expression According to TNM Stages 
Subsequently, the expression levels of circulating miR-202 were analyzed according to TNM 
stages, revealing a statistically significant difference between the expression level of each stage and 
healthy control (p < 0.001 for stage I, p < 0.001 for stage II, and p = 0.001 for stage III; Figure 2a). 
Importantly, the positivity rate was 95% (19/20) for early stage (stages I and II; Figure 2a). 
Figure 1. Diagnostic utility of circulating miR-202 in plasma for breast cancer. (a) Heatmap of circulating
miR-202 in breast cancer patients and healthy controls. The color scheme is based on the gene expression
level with upregulation in the red color and down regulation in the blue color. (b) The receiver operator
characteristic curve (ROC) analysis of circulating miR-202. (c) Sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of circulating miR-202.
3.3. Circulating miR-202 Expression According to TNM Stages
Subsequently, the expression levels of circulating miR-202 were analyzed according to TNM stages,
revealing a statistically significant difference between the expression level of each stage and healthy
control (p < 0.001 for stage I, p < 0.001 for stage II, and p = 0.001 for stage III; Figure 2a). Importantly,
the positivity rate was 95% (19/20) for early stage (stages I and II; Figure 2a).
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To investigate the prediction power for diagnosis of breast cancer, the risk of breast cancer for
miR-202 was determined. We found that miR-202 conferred a 4.3-fold (95% CI, 1.6–11.7, p < 0.001) at
stage I, 3.9-fold (95% CI, 1.4–10.3, p < 0.001) at stage II, 3.4-fold (95% CI, 1.3–9.0, p < 0.001) at stage III,
and 9.6 fold (95% CI, 3.3–28.3, p < 0.001) in total breast cancer patients (Figure 2b).
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Figure 2. Expression levels of circulating miR-202 according to Tumor-Node-Metastasis (TNM) stage.
(a) The relative expression of circulating miR-202 in plas a of breast cancer patients and healthy
controls at different breast cancer stages (stages I, II, and III). (b) Odds ratios (ORs) of circulating
miR-202 according to TNM stage.
4. Discussion
The detection of circulating biomarkers can provide the understanding of their clinical implications
and their potential use in a liquid biopsy for the diagnosis and treatment of cancer [33,34].
Among circulating biomarkers, circulating miRNAs are abundant in the circulatory system of blood and
are resistant to RNase-mediated degradation. Circulating miRNAs re also stable in harsh conditions,
including bipolar pH, extended storage, freeze–thaw cycl s, and in formalin-fixed, paraffin-embed ed
tissue sections [35,36]. In thi study, to evaluate circulating miR-202 as a diagnostic tool for bre st
cancer, the perf rmanc charact istics of its se sitivity, specifi ity, PPV, and NPV w re determined
using plasma samples of the breast c ncer patient .
In a previous study, the diagnostic potential of i -202 as eter ined in whole blood samples
of 24 breast cancer patients and 24 healthy control using RT-qPCR [37]. miR-202 was found to be highly
expressed in breast cancer and the AUC for miR-202 was 0.68. In addition, Joosse et al. [24] reported
that the miR-202 levels were elevated in a cohort of breast cancer patients (n = 102) compared with
those in healthy controls (n = 37), which is identical to the results of this study. Our result showed that
the sensitivity and specificity of circulating miR-202 were 90.0% and 93.0%, respectively. The AUC
value was 0.95 (95% CI = 0.88–1.02, p < 0.0001).
Numerous studies focus on improving or developing a treatment for improved prognosis; however,
one of the most promising approaches is to detect the cancer at the early stage. The mammography and
ultrasound are currently the standard diagnostic tools, proven to be useful for the detection of early
stage breast cancer. However, the need for a new minimally invasive diagnostic approach is necessary
to complement the mammography and improve the detection rates and breast cancer screening
regulations. The specificity of mammography is more than 95%, but the sensitivity is between 67% and
95%, and is highly dependent on diverse factors such as age, breast density, and the professional
experi nce of the investigator [38,39]. We found that miR-202 was significantly upregulated in the
plasma samples of early stage breast cancer (p < 0.001). Positivity rate was 100% (10/10) for stages I,
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90% (9/10) for stage II, and 80% (8/10) for stage III. In addition, risk of breast cancer for miR-202 was
9.6-fold in the plasma of breast cancer patients compared with that in the plasma of healthy controls.
Several studies have investigated the circulating miRNAs for breast cancer. Chen et al. showed that
the expression levels of miR-127-3p, miR-148b, miR-409-3p, miR-376a, miR-376c, miR-652, and miR-801
in the plasma of breast cancer patients were higher than the plasma of healthy controls. The diagnostic
potential of these seven circulating miRs combined in 120 breast cancer patients showed an AUC value
of 0.81 (95% CI 0.72–0.91) [40]. Additionally, Schrauder et al. reported that serum concentrations of
miR-106a-5p and miR454-3p were higher in cancer patients than in healthy controls, whereas those of
miR-195-5p, miR-495, and miR-34a-5p were downregulated in breast cancer patients. miR-195-5p and
miR-495 can help differentiate between breast cancer and healthy controls with AUC values (sensitivity,
specificity) of 0.901 (77.8%, 100%) and 0.901 (100%, 66.7%), respectively [37]. The sensitivity and
specificity of miR-202 were comparable to those of other miRs for the breast cancer diagnostic method.
5. Conclusions
Our results show that miR-202-specific RT-qPCR may emerge as a useful tool in the diagnosis
of breast cancer, and especially at its early stage. The limitation of this study was the small sample
size from a single institution. Therefore, it is necessary to conduct additional studies using a large
number of samples from the patients with various stages of breast cancer from multiple centers.
Metastasis is one of the major causes of cancer-related deaths where early prediction can increase the
survival rate. Investigation of the relationship between prognosis and the level of circulating miR-202
is also necessary.
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